Theranexus Société Anonyme (EPA:ALTHX)

Market Cap	25.30M
Revenue (ttm)	876.13K
Net Income (ttm)	-2.94M
Shares Out	9.44M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	6.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,959
Average Volume	88,858
Open	2.680
Previous Close	2.680
Day's Range	2.550 - 2.700
52-Week Range	0.261 - 3.660
Beta	1.90
RSI	54.45
Earnings Date	Sep 25, 2025

About EPA:ALTHX

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.